Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer

Status: active

Patients who have been diagnosed with a head and/or neck cancer commonly develop oral mucositis (OM). The purpose of this study is to estimate the effect of Caphosol on OM and to evaluate if Caphosol had any effect on clinical outcomes which include quality of life, oral intake, swallowing function and pain.

Inclusion Criteria

Diagnosed Head and Neck Cancer patients with planned Radiation therapy
Have at least one of 10 pre-defined anatomic mucosal subsites on view
Age >/= 18 years
Life expectancy >/= 6 months
Planned RT to the head/neck
Must be able to perform oral rinse

Exclusion Criteria

Active infections of oral cavity
physiologic condition that precludes the use of an oral rinse
Hypersensitivity to Caphosol ingredients
Presence of mucosal ulceration at baseline
Poorly controlled hypertension, DM or other serious medical/psychiatric illness

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.